^
    1d
    Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial (clinicaltrials.gov)
    P2, N=88, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1)
    |
    KRAS mutation • BRCA2 mutation • BRCA1 mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Talzenna (talazoparib) • ZEN-3694
    1d
    CITADEL-123: Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma (clinicaltrials.gov)
    P1, N=7, Completed, Theragnostics Ltd | Recruiting --> Completed | N=67 --> 7 | Trial completion date: Apr 2027 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    IDH wild-type
    5d
    Development of Stearic Acid Nanoemulsion for Therapeutic Delivery of Talazoparib Against Breast Cancer. (PubMed, Pharmaceutics)
    SANE-TZL markedly improves the delivery efficiency and antitumor activity of TZL in breast cancer models while maintaining a favorable safety profile. By combining a functional stearic acid carrier with TZL, this nanoemulsion formulation represents a safe and potent strategy to enhance PARP inhibitor-based chemotherapy in breast cancer, and it may provide a basis for further mechanistic studies on DNA damage response modulation.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • SLFN11 (Schlafen Family Member 11) • RAD51 (RAD51 Homolog A)
    |
    Talzenna (talazoparib)
    5d
    Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51. (PubMed, Molecules)
    Notably, the dual inhibition of IDO1 and PARP1/2 specifically reduced the expression of HR core genes and proteins, such as BRCA1 and RAD51, which may contribute to impaired DNA-damage repair and increased sensitivity to Olaparib. In summary, targeting both IDO1 and PARP1/2 represents a promising combination therapy for BRCA-proficient TNBC.
    Journal • BRCA Biomarker • PARP Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset) • RAD51 (RAD51 Homolog A) • IDO1 (Indoleamine 2,3-dioxygenase 1)
    |
    Lynparza (olaparib) • epacadostat (INCB024360)
    5d
    MOB2 Loss Sensitizes Lung Cancer Cells to PARP Inhibition Through p53-Dependent DNA Damage Signaling. (PubMed, Curr Issues Mol Biol)
    hMOB2 depletion sensitized A549 cells to olaparib and rucaparib, resulting in a marked reduction in long-term clonogenic survival. Sensitization required functional p53, as it was absent in p53-null cells but restored upon p53 re-expression. These findings suggest that hMOB2 contributes to PARP inhibitor responses in lung cancer cells and underscore the complexity of PARP inhibitor sensitivity beyond classical HR deficiency.
    Journal • PARP Biomarker
    |
    CASP3 (Caspase 3)
    |
    Lynparza (olaparib) • Rubraca (rucaparib)
    5d
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=404, Active, not recruiting, BeOne Medicines | Enrolling by invitation --> Active, not recruiting
    Enrollment closed
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • Ziihera (zanidatamab-hrii) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    7d
    Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. (PubMed, Nat Med)
    These data suggest that a subset of HRD PC may derive prolonged benefit from PARP-ICB maintenance and support further development of biomarker-guided precision immunotherapy strategies in PC. ClinicalTrials.gov identifier: NCT04666740 .
    P2 data • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2)
    |
    BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    7d
    Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production. (PubMed, J Immunother Cancer)
    Telmisartan depletes tumor PD-L1 but has significant PD-L1-independent clinical translational potential to improve PARPi in BRCA wild-type (WT) tumors and augment tumor immunogenicity.
    Journal
    |
    BRCA (Breast cancer early onset) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    BRCA wild-type
    |
    Lynparza (olaparib)
    7d
    A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial Cancer. (PubMed, Clin Cancer Res)
    The combination of olaparib plus pembrolizumab has promising activity with durable responses in patients with persistent or recurrent CN-H/p53-abnormal endometrial cancer. Molecular biomarkers may be helpful for patient selection in future studies of this combination.
    P2 data • Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • HRD (Homologous Recombination Deficiency) • POLE (DNA Polymerase Epsilon)
    |
    TP53 mutation • POLE mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    7d
    Niraparib in Patients With Pancreatic Cancer (clinicaltrials.gov)
    P2, N=32, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed
    Trial completion
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CHEK2 (Checkpoint kinase 2)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation
    |
    Zejula (niraparib)
    8d
    QUEST: A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P2, N=136, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Zejula (niraparib) • abiraterone acetate • prednisone • cetrelimab (JNJ-63723283)
    8d
    Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer (clinicaltrials.gov)
    P2, N=79, Completed, University of Colorado, Denver | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Feb 2026
    Trial completion • Trial completion date
    |
    Rubraca (rucaparib)